76 / 89
76
REFERÊNCIAS
1.
Centre for Evidence Based Medicine [Internet]. Oxford:
University of Oxford; 2011. [cited 2012 Nov 21]. Available
from: http:/
/ www.cebm.net2.
Palumbo A, Anderson K. Multiple myeloma. N Engl J
Med 2011;364:1046-60.
3.
Hungria VT, Maiolino A, Martinez G, Colleoni GW,
Coelho EO, Rocha L, et al. Confirmation of the utility of
the International Staging System and identification of a
unique pattern of disease in Brazilian patients with
multiple myeloma. Haematologica 2008;93:791-2.
4.
Korde N, Kristinsson SY, Landgren O. Monoclonal
gammopathy of undetermined significance (MGUS) and
smoldering multiple myeloma (SMM): novel biological
insights and development of early treatment strategies.
Blood 2011;117:5573-81.
5.
Dimopoulos M, Kyle R, Fermand JP, Rajkumar SV, San
Miguel J, Chanan-Khan A, et al. Consensus
recommendations for standard investigative workup:
report of the International Myeloma Workshop
Consensus Panel 3. Blood 2011;117:4701-5.
6.
Vermeersch P, Van Hoovels L, Delforge M, Mariën G,
Bossuyt X. Diagnostic performance of serum free light
chain measurement in patients suspected of a monoclonal
B-cell disorder. Br J Haematol 2008;143:496-502.
7.
Frébet E, Abraham J, Geneviève F, Lepelley P, Daliphard
S, Bardet V, et al. A GEIL flow cytometry consensus
proposal for quantification of plasma cells: application to
differential diagnosis between MGUS and myeloma.
Cytometry B Clin Cytom 2011;80:176-85.